Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 1.00 |
| ▸ | PLG | P00747 | 16/20 | 1.00 |
| ▸ | F10 | P00742 | 6/20 | 1.00 |
| ▸ | F2 | P00734 | 5/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 5/20 | 1.00 |
| ▸ | PLAT | P00750 | 3/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 1.00 |
| ▸ | HPN | P05981 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178270 | 1.00 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL20675070 | 1.00 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Hydrochloric Acid SCHEMBL31637457 | 0.99 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| SCHEMBL437042 | 0.91 | PLAU (0.90) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL30912299 | 0.91 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL20674935 | 0.91 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL12618906 | 0.91 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL20669283 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL437037 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL31331918 | 0.91 | PLAU (1.00) | PLAUPLGF10F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2025-12-23 | — | — | US | disclosed |
| US-20240350461-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2024-10-24 | — | — | US | disclosed |
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | REDHILL BIOPHARMA LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| EP-4117630-A1 | TREATMENT OF CORONAVIRUS INFECTION | RedHill Biopharma Ltd. (IL) | 2023-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918560-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
| US-20240350461-A1 | SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
| US-12502381-B2 | Serine protease inhibitor for treating coronavirus infection | PRSS1, ACE, TMPRSS2 | PLAU 67/4885PLG 95/4885F10 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.